乳腺癌的雌激素受体显像

孟召伟; 董峰; 谭建

乳腺癌的雌激素受体显像

孟召伟 , 董峰 , 谭建

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 3: (157-159)

引用本文:

Citation:

乳腺癌的雌激素受体显像

300052 天津, 天津医科大学总医院核医学科

通讯作者: 孟召伟, james-mencius@eyou.com ;

中图分类号: R817.4

Estrogen receptor imaging in breast cancer

Department of Nuclear Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China

Corresponding author: MENG Zhao-wei, james-mencius@eyou.com ;

CLC number: R817.4

摘要: 雌激素对乳腺癌的作用是通过与雌激素受体(ER)的结合来实现的,已发现ER有两个亚型.¹⁸F-16α-氟雌二醇(¹⁸F-FES)核素受体显像可显示出乳腺癌病灶有生物活性的ER,若乳腺癌原发灶或转移灶对¹⁸F-FES标准化摄取值(SUV)高,则内分泌治疗的有效预测值升高;若在他莫西芬治疗前和治疗后7~10 d分别行¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)PET和¹⁸F-FES PET双核素显像,对于有效组治疗后¹⁸F-FES PET的SUV下降,¹⁸F-FDG PET的SUV升高.
- 乳腺肿瘤 /
- 受体,雌激素 /
- 雌二醇 /
- 氟脱氧葡萄糖F18
Abstract: Estrogen plays an important role in breast cancer by binding with estrogen receptor(ER).There are two ER subtypes(α and β).16α-¹⁸F-fluoroestradiol (¹⁸F-FES) imaging can detect biologically active ER in breast cancer. This nuclear imaging technique can show the effectiveness of antiestrogen treatment and has deep implications on prognosis of breast cancer. Quantitative ¹⁸F-FES uptake and antiestrogen treatment response are significantly associated; baseline ¹⁸F-FES imaging demonstrated that tumors in the patients who responded to tamoxifen had a higher mean standard uptake value for ¹⁸F-FES than the nonresponders. After tamoxifen treatment,the mean tumor ¹⁸F-fluoroestradio uptake decreased consistently with binding of tamoxifen and its bioactive metabolites to ERs. While in the metabolic flare responders, the tumor ¹⁸F-fluorodeoxyglucose uptake increased 7 to 10 days after tamoxifen treatment
- Breast neoplasms /
- Receptors,estrogen /
- Estradiol /
- Fluorodeoxyglucose F18
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Beral V,Million Women Study Collaborators.Breast cancer and hormone-replacement therapy in the Million Women Study.Lancet,2003,362(9382):419-427.
[2]	Chlebowski RT,Hendrix SL,Langer RD,et al.Influence of estrogens plus progestin on breast cancer and mammography in healthy postmenopausal women:the women's health initiative randomized trial.J Am Med Assoc,2003,289(24):3243-3253.
[3]	Weihua Z,Andersson S,Cheng G,et al.Update on estrogen signaling.FEBS Letters,2003,546(1):17-24.
[4]	Bardin A,BouIIe N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.Endocr Relat Cancer,2004,11(3):537-551.
[5]	Eubank WB,Mankoff DA.Evolving role of positron emission tomography in breast cancer imaging.Semin Nucl Med,2005,35(2):84-99.
[6]	Linden HM,Stekhova SA,Link JM,et al.Quantitative fluoroe-stradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.J Clin Oncol,2006,24(18):2793-2799.
[7]	Mankoff DA,Peterson LM,Tewson TJ,et al.[¹⁸F]-fluoroestradiol radiation dosimetry in human PET studies.J Nucl Med,2001,42(4):679-684.
[8]	Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:Indicator of hormone responsiveness in advanced breast cancer,j Clin Oncol,2001,19(11):2797-2803.
[9]	Yoo J,Dence CS,Sharp TL,et al.Synthesis of an estrogen receptor beta-selective radioligand:5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxy-phenyl) pentanenitrile and comparison of in vivo distribution with 16alpha-[¹⁸F]fluoro-17beta-estradiol.J Med Chem,2005,48 (20):6366-6378.
[10]	Vijaykumar D,Al-Qahtani MH,Welch MJ,et al.Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand:[¹⁸F] propyl pyrazole trioi.Nucl Med Biol,2003,30(4):397-404.
[11]	Aliaga A,Rousseau JA,Ouellette R,et al.Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.Nucl Med Biol,2004,31(6):761-770.

[1]	林美福 , 陈文新 , 周硕 , 郭莘 , 陈彩龙 , 陈国宝 , 戴红峰 . ¹⁸F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用. 国际放射医学核医学杂志, 2013, 37(4): 216-220. doi: 10.3760/cma.j.issn.1673-4114.2013.04.007
[2]	刘义明 , 叶爱霞 , 钟娆霞 , 莫伟 , 高卉 . 血清β-人绒毛膜促性腺激素、孕酮、雌二醇值对早期正常妊娠、妊娠流产和异位妊娠的诊断价值. 国际放射医学核医学杂志, 2009, 33(2): 102-104. doi: 10.3760/cma.j.issn.1673-4114.2009.02.012
[3]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[4]	刘建井 , 边海曼 , 马文娟 , 王子阳 , 陈薇 , 朱磊 , 戴东 , 徐文贵 . 基于¹⁸F-FDG PET/CT图像建立的多元影像组学模型对乳腺癌原发灶HER-2表达状态的预测价值. 国际放射医学核医学杂志, 2022, 46(7): 430-440. doi: 10.3760/cma.j.cn121381-202203015-00206
[5]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
[6]	孙琳 , 高再荣 , 张永学 . ¹⁸F-氟代脱氧葡萄糖PET-CT用于恶性肿瘤治疗疗效评估与监测. 国际放射医学核医学杂志, 2006, 30(6): 328-331.
[7]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[8]	张玉娜 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
[9]	袁建伟 , 杨劼 , 贺小红 , 张培培 , 肖菊梅 , 王颖 . ¹⁸F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值. 国际放射医学核医学杂志, 2013, 37(4): 199-202. doi: 10.3760/cma.j.issn.1673-4114.2013.04.003
[10]	赵洪刚 , 董华 , 顾燕 , 张遵城 . 早孕药物流产后动态观察血清性激素变化的临床价值. 国际放射医学核医学杂志, 2009, 33(5): 283-285. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.008

点击查看大图

计量

文章访问数: 1516
HTML全文浏览量: 152
PDF下载量: 2

乳腺癌的雌激素受体显像

通讯作者: 孟召伟, james-mencius@eyou.com;

300052 天津, 天津医科大学总医院核医学科

收稿日期: 2006-09-28

关键词:

摘要: 雌激素对乳腺癌的作用是通过与雌激素受体(ER)的结合来实现的,已发现ER有两个亚型.¹⁸F-16α-氟雌二醇(¹⁸F-FES)核素受体显像可显示出乳腺癌病灶有生物活性的ER,若乳腺癌原发灶或转移灶对¹⁸F-FES标准化摄取值(SUV)高,则内分泌治疗的有效预测值升高;若在他莫西芬治疗前和治疗后7~10 d分别行¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)PET和¹⁸F-FES PET双核素显像,对于有效组治疗后¹⁸F-FES PET的SUV下降,¹⁸F-FDG PET的SUV升高.